About MeiraGTx Holdings plc
https://www.meiragtx.comMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases.
CEO
Alexandria Forbes
Compensation Summary
(Year 2024)
Salary $840,000
Bonus $2,195,703
Stock Awards $3,819,200
All Other Compensation $20,700
Total Compensation $6,875,603
Industry Biotechnology
Sector Healthcare
Went public June 8, 2018
Method of going public IPO
Full time employees 375
ETFs Holding This Stock
Summary
Total 57
Showing Top 3 of 57
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Outperform 1
Overweight 1
Showing Top 3 of 3
Price Target
Target High $20
Target Low $16
Target Median $18
Target Consensus $18
Institutional Ownership
PERCEPTIVE ADVISORS LLC
Shares:12.63M
Value:$94.06M
SANOFI
Shares:12.2M
Value:$90.87M
JOHNSON & JOHNSON
Shares:6.64M
Value:$49.48M
Summary
% Of Shares Owned 80.33%
Total Number Of Holders 139
Showing Top 3 of 139
Market Cap $585.97 M
52w High $9.73
52w Low $4.55
P/E -3.53
Volume 424.12K
Outstanding Shares 80.49M
About MeiraGTx Holdings plc
https://www.meiragtx.comMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $410K ▼ | $46.15M ▲ | $-50.51M ▼ | -12.32K% ▼ | $-0.62 ▼ | $-44.01M ▼ |
| Q2-2025 | $3.69M ▲ | $45.81M ▲ | $-38.8M ▲ | -1.05K% ▲ | $-0.48 ▲ | $-32.57M ▲ |
| Q1-2025 | $1.93M ▼ | $42.14M ▲ | $-39.98M ▼ | -2.08K% ▼ | $-0.51 ▼ | $-33.86M ▼ |
| Q4-2024 | $21.39M ▲ | $41.07M ▲ | $-39.4M ▼ | -184.19% ▲ | $-0.5 ▲ | $-33.06M ▼ |
| Q3-2024 | $10.91M | $38.97M | $-39.33M | -360.49% | $-0.55 | $-32.71M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $14.84M ▼ | $189.47M ▼ | $230.03M ▲ | $-40.56M ▼ |
| Q2-2025 | $32.17M ▼ | $198.72M ▼ | $195.76M ▲ | $2.96M ▼ |
| Q1-2025 | $66.52M ▼ | $224.01M ▼ | $190.91M ▼ | $33.1M ▼ |
| Q4-2024 | $103.66M ▼ | $269.75M ▼ | $201.92M ▼ | $67.83M ▼ |
| Q3-2024 | $122.87M | $299.49M | $203.75M | $95.74M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-50.51M ▼ | $-12.21M ▲ | $-547K ▲ | $-219K ▼ | $-17.32M ▲ | $-12.82M ▲ |
| Q2-2025 | $-38.8M ▲ | $-43.95M ▼ | $-761K ▲ | $5.45M ▲ | $-34.19M ▲ | $-45.18M ▼ |
| Q1-2025 | $-39.98M ▼ | $-36.83M ▼ | $-1.71M ▼ | $1.71M ▼ | $-37.06M ▼ | $-38.54M ▼ |
| Q4-2024 | $-39.4M ▼ | $-23.28M ▲ | $-1.22M ▲ | $4.24M ▼ | $-19.36M ▼ | $-24.49M ▲ |
| Q3-2024 | $-39.33M | $-25.02M | $-1.31M | $49.96M | $24M | $-25.75M |
CEO
Alexandria Forbes
Compensation Summary
(Year 2024)
Salary $840,000
Bonus $2,195,703
Stock Awards $3,819,200
All Other Compensation $20,700
Total Compensation $6,875,603
Industry Biotechnology
Sector Healthcare
Went public June 8, 2018
Method of going public IPO
Full time employees 375
ETFs Holding This Stock
Summary
Total 57
Showing Top 3 of 57
Ratings Snapshot
Rating : C
Discounted Cash Flow 1
Return On Equity 5
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 1
Outperform 1
Overweight 1
Showing Top 3 of 3
Price Target
Target High $20
Target Low $16
Target Median $18
Target Consensus $18
Institutional Ownership
PERCEPTIVE ADVISORS LLC
Shares:12.63M
Value:$94.06M
SANOFI
Shares:12.2M
Value:$90.87M
JOHNSON & JOHNSON
Shares:6.64M
Value:$49.48M
Summary
% Of Shares Owned 80.33%
Total Number Of Holders 139
Showing Top 3 of 139